New drug combo aims to shrink tumors in advanced breast cancer
NCT ID NCT07294508
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining two experimental drugs (HLX22 and HLX87) works better as a first treatment for HER2-positive breast cancer that has returned or spread. About 706 adults with advanced or metastatic breast cancer will participate. The main goals are to see how many patients' tumors shrink and how long the cancer stays under control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2 + BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Step drug combo outsmart advanced HER2-Positive breast cancer?
- Can an oral chemo pill boost breast cancer treatment?
- Could a Triple-Drug attack before surgery eliminate more breast cancer in older women?
- Blood test may reveal if breast cancer treatment is working
- New vaccine combo aims to supercharge immune attack on breast cancer
- New study tests targeted pill combo for advanced breast cancer in Real-World settings